Since fall 2024, the Federal Office of Public Health in Switzerland has recommended that newborns
receive a new type of vaccination in their first week of life between October and March.
If the parents consent, newborns are injected with an antibody that is supposed to protect against infection with the RS virus.
This RS virus can cause colds and flu-like illnesses in infants.
The product is the antibody Nirsevimab, trade name Beyfortus.
It is not an actual vaccination, but an antibody that is produced in the laboratory and injected into
the newborn. It is also called "passive immunization".
In Germany, Austria and France, the administration of the antibody to newborns is also recommended and implemented.
Once again, critical voices from doctors and researchers on the widespread administration of
this antibody to newborns are being kept quiet.
That's why Kla.TV is letting some of these voices have their say today. For further
information, please refer to the source credits.
Doctors for individual vaccination decisions write the following on RSV immunization under the heading "RSV
prophylaxis: Passive immunization that actively benefits pharmaceutical manufacturers":
"The Standing Vaccination Commission in Germany has issued a recommendation for prophylaxis
against RSV infections for all newborns and infants.
However, this only reduces the risk of having to be hospitalized due to an RSV infection
of the lower respiratory tract by 1 percent.
The consequences of treatment, which can result from side effects, also remain unnoticed.
The known side effects of nirsevimab administration to date include redness and pain at the injection site as well as fever.
Pharmaceutical manufacturers have already reacted to the coming mass immunization and lowered the price of nirsevimab.
Nevertheless, the recommendation costs the healthcare system more than 200 million euros a year, which will be lacking elsewhere.
The physician Dr. Alexander Konietzky writes further: "The fact that in future all infants of a year group will be treated
prophylactically before leaving the maternity clinics with consequences that have not yet been sufficiently
researched is hardly compatible with medical ethics."
Independent French researchers have also commented on RSV immunization. TKP, the blog for science &
politics, already reported on this on January 5, 2024.
In interviews with The Defender, French researchers explained that data from the French National Institute for Statistics and
Economic Studies indicate an unlikely high mortality rate for infants aged 2 to 6 days in France in September and October 2023.
According to the researchers, this increase coincides with the introduction of Beyfortus in
French hospitals, which began on September 15, 2023.
Dr. Meryl Nass, an internist and biological warfare epidemiologist and member of the Children's Health Defense
Scientific Advisory Committee, also told The Defender:
[Voiceover: "The administration of drugs or biologics to newborns should be done with extreme caution,
not to mention a novel injected monoclonal antibody.
It is not possible to say whether the infant will be harmed by the injection if we do not yet know how
healthy the newborn is and how it normally behaves.
This should be a major warning signal for both manufacturers and parents."
Back in November 2024, Renate Holzeisen, a member of parliament from South Tyrol, sharply
criticized the widespread use of the antibody in newborns.
Despite the negative opinion of the Italian health authority ISS, the active substance will now
be administered to all newborns in South Tyrol.
The ISS had warned that the drug would only be of limited benefit given the low incidence of the disease and that
there were potentially serious risks for newborn babies.
Researchers from Japan, who are independent of the pharmaceutical industry, also warn
against the use of the antibody in newborns.
They write: A combined analysis we conducted of three large randomized and controlled trials showed a
significantly higher mortality rate, probably due to an increase in non-RSV-related disease, especially thrombosis.
Ladies and gentlemen, despite these warning voices, the recommendation to administer the RSV
antibody is not being withdrawn or questioned.
This clearly shows how much influence the pharmaceutical industry has on vaccination recommendations worldwide.
And since coronavirus, it has become clear to people that these recommendations can no longer be trusted.
Therefore, continue to question all vaccination recommendations in the future and inform yourself about voice and dissent.